Shoutbox » Late-stage Drug Candidates (Phase III & Registration Phase)

Pulmonary Arterial Hypertension (PAH) Market Boosted by Recently-approved Drugs Dirk Nowitzki Jersey , to Reach US$5.19 bn Health Articles | March 31, 2016

Global Pulmonary Arterial Hypertension (PAH) Market was valued at USD 4.04 billion in 2013 and is expected to grow at a CAGR of 2.3% from 2014 to 2020, to reach an estimated value of USD 5.19 billion in 2020.



Pulmonary arterial hypertension is when the blood pressure inside the small arteries within the lungs increases. PAH can cause swelling of legs, fainting, dizziness, and shortness of breath Wesley Matthews Jersey , among other more serious symptoms. One of the biggest problems that a patient with PAH suffers is an extremely low tolerance to exercise. PAH can escalate into pulmonary vascular resistance and cause the failure of the right ventricle.

According to the report, the primary driver for the聽global PAH market is the list of newly-approved drugs and medical products aimed at treating PAH. A large number of medical products are already approved, while more are still in the pipeline. Another factor promoting the growth of the global PAH market is the increasing number of leaps taken in research and development efforts, aided by government policies and other initiatives.

The report provides a segmented analysis of the global PAH market. These segments are sorted within the categories of drug class and geography. The report also provides an extensive analysis of the pipeline drugs in the global PAH market.

In terms of drug class, the global PAH market is segmented into soluble guanylate cyclase (sGC) stimulators, phosphodiesterase-5 (PDE-5) inhibitors DeAndre Jordan Jersey , endothelin receptor antagonists (ERAs), and prostacyclin and prostacyclin analogs. Of these, the report’s authors have put the prostacyclin and prostacyclin analogs segment ahead of the ERA segment, which means that the segment will lead the global PAH market by 2023, surpassing the current leader, ERAs.

The report’s geographical segmentation of the global PAH market reveals Asia Pacific to be the fastest-growing region for the given forecast period. The growth rate of this region is attributed to major opportunities that will be found in Australia Dennis Smith Jr. Jersey , New Zealand, Japan, China, and India. Enterprises operating in these regions could take advantage of these opportunities and increase their profits and presence in the market.

The report, however, states one of the major restraints on the global PAH market as the challenges faced by the Rest of the World PAH market. The report’s study shows that most of the nations in the Rest of the World region possess a low level of awareness of this market’s products. Therefore Luka Doncic Jersey , this region is showing a much slower growth rate when compared to the regions of North America or Europe.

The key players in the global pulmonary arterial hypertension market are United Therapeutics Corp., Novartis International AG, Pfizer Inc., GlaxoSmithKline plc, Bayer HealthCare, Gilead Sciences Inc. Harrison Barnes Jersey , and Actelion Pharmaceuticals Ltd.

Key segments of the Global Pulmonary Arterial Hypertension (PAH) Market

Global Pulmonary Arterial Hypertension Market, by Drug Class
Prostacyclin and Prostacyclin Analogs
Endothelin Receptor Antagonists (ERAs)
Phosphodiesterase-5 (PDE-5) Inhibitors
Soluble Guanylate Cyclase (sGC) Stimulators

Pipeline Analysis: Pulmonary Arterial Hypertension Market
Early-stage Drug Candidates (Phase I & Phase II)
Late-stage Drug Candidates (Phase III & Registration Phase)

Download Free Sample Report Brochure: >